Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 1, 2005, Pages 22-30

  Kugelberg, Elisabeth ^a,b   Löfmark, Sonja ^c   Wretlind, Bengt ^c   Andersson, Dan I ^a,b  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibiotic resistance; Biological cost; Compensation; Supercoiling

Indexed keywords

COMPLEMENTARY DNA; DNA TOPOISOMERASE IV; NORFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MUTATION; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; BACTERIUM MUTANT; BIOFILM; DNA SUPERCOILING; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GROWTH RATE; IN VITRO STUDY; MULTIDRUG RESISTANCE; MUTATION RATE; MUTATIONAL ANALYSIS; NONHUMAN; PSEUDOMONAS AERUGINOSA; REAL TIME POLYMERASE CHAIN REACTION; REDUCTION; RNA PURIFICATION;

ANTI-INFECTIVE AGENTS; BACTERIAL PROTEINS; CULTURE MEDIA; DNA GYRASE; DNA TOPOISOMERASE IV; DNA-BINDING PROTEINS; DRUG RESISTANCE, BACTERIAL; EVOLUTION, MOLECULAR; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; NORFLOXACIN; PSEUDOMONAS AERUGINOSA; QUINOLONES; TRANSCRIPTION FACTORS;

EID: 13244256910     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh505     Document Type: Article

References (35)

1. Hancock, R. E. & Speert, D. P. (2000). Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resistance Updates 3, 247-55.
2. Lambert, P. A. (2002). Mechanisms of antibiotic resistance in Pseudomonas aeruginosa. Journal of the Royal Society of Medicine 95, Suppl.41, 22-6.
3. Doring, G., Conway, S. P., Heijerman, H. G. et al. (2000). Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. European Respiratory Journal 16 749-67.
4. Jalal, S., Ciofu, O., Hoiby, N. et al. (2000). Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrobial Agents and Chemotherapy 44, 710-2.
5. Pitt, T. L., Sparrow, M., Warner, M. et al. (2003). Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 58, 794-6.
6. Drlica, K. & Zhao, X. (1997). DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiology and Molecular Biology Reviews 61, 377-92.
7. Piddock, L. J. (1999). Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs 58, 11-18.
8. Martinez-Martinez, L., Pascual, A. & Jacoby, G. A. (1998). Quinolone resistance from a transferable plasmid. Lancet 351, 797-9.
9. Wang, M., Tran, J. H., Jacoby, G. A. et al. (2003). Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China. Antimicrobial Agents and Chemotherapy 47, 2242-8.
10. Tran, J. H. & Jacoby, G. A. (2002). Mechanism of plasmid-mediated quinolone resistance. Proceedings of the National Academy of Sciences, USA 99, 5638-42.
11. Willmott, C. J. & Maxwell, A. (1993). A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex. Antimicrobial Agents and Chemotherapy 37, 126-7.
12. Andersson, D. I. & Levin, B. R. (1999). The biological cost of antibiotic resistance. Current Opinion in Microbiology 2, 489-93.
13. Andersson, D. I. (2003). Persistence of antibiotic resistant bacteria. Current Opinion in Microbiology 6, 452-6.
14. Sanchez, P., Linares, J. F., Ruiz-Diez, B. et al. (2002). Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants. Journal of Antimicrobial Chemotherapy 50, 657-64.
15. Lea, D. E. & Coulson, C. A. (1949). The distribution of the number of mutants in bacterial populations. Journal of Genetics 49, 264-85.
16. Maisnier-Patin, S., Berg, O. G., Liljas, L. et al. (2002). Compensatory adaptation to the deleterious effect of antibiotic resistance in Salmonella typhimurium. Molecular Microbiology 46 355-66.
17. Nilsson, A. I., Kugelberg, E., Berg, O. G. et al. (2004). Experimental adaptation of Salmonella typhimurium to mice. Genetics 168, in press.
18. O'Toole, G. A., Pratt, L. A., Watnick, P. I. et al. (1999). Genetic approaches to study of biof ilms. Methods in Enzymology 310, 91-109.
19. Jalal, S. & Wretlind, B. (1998). Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. Microbial Drug Resistance 4, 257-61.
20. Oh, H., Stenhoff, J., Jalal, S. et al. (2003). Role of efflux pumps and mutations in genes for topoisomerase II and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains. Microbial Drug Resistance 9, 323-8.
21. Matsuo, M., Ohtsuka, Y., Kataoka, K. et al. (1996). Transient relaxation of plasmid DNA in Escherichia coli by fluoroquinolones. Journal of Pharmacy and Pharmacology 48, 985-7.
22. Poole, K. (2004). Efflux-mediated multiresistance, in Gram-negative bacteria. Clinical Microbiology and Infection 10 12-26.
23. Komp Lindgren, P., Karlsson, A. & Hughes, D. (2003). Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrobial Agents and Chemotherapy 47, 3222-32.
24. Mouneimne, H., Robert, J., Jarlier, V. et al. (1999). Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 43 62-6.
25. Higgins, P. G., Fluit, A. C., Milatovic, D. et al. (2003). Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa. International Journal of Antimicrobial Agents 21, 409-13.
26. Mizushima, T., Kataoka, K., Ogata, Y. et al. (1997). Increase in negative supercoiling of plasmid DNA in Escherichia coli exposed to cold shock. Molecular Microbiology 23, 381-6.
27. Menzel, R. & Gellert, M. (1983). Regulation of the genes for E. coli DNA gyrase: homeostatic control of DNA supercoiling. Cell 34, 105-13.
28. Takenouchi, T., Sakagawa, E. & Sugawara, M. (1999). Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones. Antimicrobial Agents and Chemotherapy 43, 406-9.
29. Akasaka, T., Tanaka, M., Yamaguchi, A. et al. (2001). Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrobial Agents and Chemotherapy 45, 2263-8.
30. Bagel, S., Hullen, V., Wiedemann, B. et al. (1999). Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli. Antimicrobial Agents and Chemotherapy 43, 868-75.
31. Barnard, F. M. & Maxwell, A. (2001). Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87). Antimicrobial Agents and Chemotherapy 45, 1994-2000.
32. Hudson, R. E., Bergthorsson, U., Roth, J. R. et al. (2002). Effect of chromosome location on bacterial mutation rates. Molecular Biology and Evolution 19, 85-92.
33. Giraud, E., Cloeckaert, A., Baucheron, S. et al. (2003). Fitness cost of fluoroquinolone resistance in Salmonella enterica serovar Typhimurium. Journal of Medical Microbiology 52, 697-703.
34. Gillespie, S. H., Voelker, L. L. & Dickens, A. (2002). Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Microbial Drug Resistance 8, 79-84.
35. Ince, D. & Hooper, D. C. (2003). Quinolone resistance due to reduced target enzyme expression. Journal of Bacteriology 185 6883-92.